{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T07:21:24Z","timestamp":1781421684878,"version":"3.54.1"},"reference-count":60,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2008,6,1]],"date-time":"2008-06-01T00:00:00Z","timestamp":1212278400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2008,6]]},"DOI":"10.1016\/j.euroneuro.2008.01.004","type":"journal-article","created":{"date-parts":[[2008,3,25]],"date-time":"2008-03-25T04:29:50Z","timestamp":1206419390000},"page":"422-430","source":"Crossref","is-referenced-by-count":77,"title":["Efficacy of pregabalin in depressive symptoms associated with generalized anxiety disorder: A pooled analysis of 6 studies"],"prefix":"10.1016","volume":"18","author":[{"given":"Dan J.","family":"Stein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Baldwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Baldinetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francine","family":"Mandel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2008.01.004_bib1","first-page":"28","article-title":"European Study of the Epidemiology of Mental Disorders (ESEMeD) Project. 12-Month comorbidity patterns and associated factors in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project","volume":"420","author":"Alonso","year":"2004","journal-title":"Acta Psychiatr. Scand., Suppl."},{"key":"10.1016\/j.euroneuro.2008.01.004_bib2","series-title":"Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)","author":"American Psychiatric Association","year":"1994"},{"key":"10.1016\/j.euroneuro.2008.01.004_bib3","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.eurpsy.2004.09.035","article-title":"Prevalence and impact of generalized anxiety disorder and major depression in primary care in Belgium and Luxemburg: the GADIS study","volume":"20","author":"Ansseau","year":"2005","journal-title":"Eur. Psychiatr."},{"key":"10.1016\/j.euroneuro.2008.01.004_bib4","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1176\/appi.ajp.161.12.2163","article-title":"The Hamilton Depression Rating Scale: has the gold standard become a lead weight?","volume":"161","author":"Bagby","year":"2004","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2008.01.004_bib5","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1177\/0269881105059253","article-title":"Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology","volume":"19","author":"Baldwin","year":"2005","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2008.01.004_bib6","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3109\/15622970209150621","article-title":"World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive\u2013compulsive and posttraumatic stress disorders","volume":"3","author":"Bandelow","year":"2002","journal-title":"World J. Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2008.01.004_bib7","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1600-0447.1975.tb00002.x","article-title":"Qualitative rating of depressive states","volume":"51","author":"Bech","year":"1975","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.euroneuro.2008.01.004_bib8","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/j.1600-0447.1981.tb00676.x","article-title":"The Hamilton Depression Scale. Evaluation of objectivity using logistic models","volume":"63","author":"Bech","year":"1981","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.euroneuro.2008.01.004_bib9","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1192\/bjp.160.2.206","article-title":"The Hamilton scales and the Hopkins Symptom Checklist (SCL-90). A cross-national validity study in patients with panic disorders","volume":"160","author":"Bech","year":"1992","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2008.01.004_bib10","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s00213-002-1147-6","article-title":"Citalopram dose\u2013response revisited using an alternative psychometric approach to evaluate clinical effects of four fixed citalopram doses compared to placebo in patients with major depression","volume":"163","author":"Bech","year":"2002","journal-title":"Psychopharmacology (Berl)."},{"key":"10.1016\/j.euroneuro.2008.01.004_bib11","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/da.1070","article-title":"Infrequency of \u201cpure\u201d GAD: impact of psychiatric comorbidity on clinical course","volume":"14","author":"Bruce","year":"2001","journal-title":"Depress. Anxiety"},{"key":"10.1016\/j.euroneuro.2008.01.004_bib12","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1176\/ajp.148.11.1512","article-title":"Follow-up and family study of anxious depression","volume":"148","author":"Clayton","year":"1991","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2008.01.004_bib58","series-title":"Statistical power analysis for the behavioral sciences, 2nd ed","author":"Cohen","year":"1988"},{"key":"10.1016\/j.euroneuro.2008.01.004_bib13","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1002\/art.20983","article-title":"Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial","volume":"52","author":"Crofford","year":"2005","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.euroneuro.2008.01.004_bib14","first-page":"1086","article-title":"Stimulus-dependent modulation of [(3)H]norepinephrine release from rat neocortical slices by gabapentin and pregabalin","volume":"295","author":"Dooley","year":"2000","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.euroneuro.2008.01.004_bib15","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0304-3940(00)00769-2","article-title":"Inhibition of K(+)-evoked glutamate release from rat neocortical and hippocampal slices by gabapentin","volume":"280","author":"Dooley","year":"2000","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.euroneuro.2008.01.004_bib16","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/syn.10094","article-title":"Preferential action of gabapentin and pregabalin at P\/Q-type voltage-sensitive calcium channels: inhibition of K+-evoked [3H]-norepinephrine release from rat neocortical slices","volume":"45","author":"Dooley","year":"2002","journal-title":"Synapse"},{"key":"10.1016\/j.euroneuro.2008.01.004_bib17","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1212\/01.WNL.0000055433.55136.55","article-title":"Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial","volume":"60","author":"Dworkin","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.euroneuro.2008.01.004_bib18","first-page":"40","article-title":"Targeting treatment in patients with mixed symptoms of anxiety and depression","volume":"51","author":"Fawcett","year":"1990","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2008.01.004_bib19","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0304-3959(03)00173-8","article-title":"Pregabalin and gabapentin reduce release of substance P and CGRP from rat spinal tissues only after inflammation or activation of protein kinase C","volume":"105","author":"Fehrenbacher","year":"2003","journal-title":"Pain"},{"key":"10.1016\/j.euroneuro.2008.01.004_bib20","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/01.jcp.0000084032.22282.ff","article-title":"A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder","volume":"23","author":"Feltner","year":"2003","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2008.01.004_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/sj.bjp.0703794","article-title":"Pregabalin may represent a novel class of anxiolytic agents with a broad spectrum of activity","volume":"132","author":"Field","year":"2001","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.euroneuro.2008.01.004_bib22","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0028-3908(01)00172-1","article-title":"Inhibition of neuronal Ca(2+) influx by gabapentin and pregabalin in the human neocortex","volume":"42","author":"Fink","year":"2002","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.euroneuro.2008.01.004_bib23","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.pain.2005.02.032","article-title":"Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens","volume":"115","author":"Freyhagen","year":"2005","journal-title":"Pain"},{"key":"10.1016\/j.euroneuro.2008.01.004_bib24","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.2044-8341.1959.tb00467.x","article-title":"The assessment of anxiety states by rating","volume":"32","author":"Hamilton","year":"1959","journal-title":"Br. J. Med. Psychol."},{"key":"10.1016\/j.euroneuro.2008.01.004_bib25","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","article-title":"A rating scale for depression","volume":"23","author":"Hamilton","year":"1960","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.euroneuro.2008.01.004_bib26","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1017\/S0033291706007367","article-title":"The impact of generalized anxiety disorder and stressful life events on risk for major depressive episodes","volume":"36","author":"Hettema","year":"2006","journal-title":"Psychol. Med."},{"key":"10.1016\/j.euroneuro.2008.01.004_bib27","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S0025-7125(05)70336-9","article-title":"Generalized anxiety disorder. An important clinical concern","volume":"85","author":"Hidalgo","year":"2001","journal-title":"Med. Clin. North. Am."},{"key":"10.1016\/j.euroneuro.2008.01.004_bib28","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1017\/S0033291702005512","article-title":"DSM-IV generalized anxiety disorder in the Australian National Survey of Mental Health and Well-being","volume":"32","author":"Hunt","year":"2002","journal-title":"Psychol. Med."},{"key":"10.1016\/j.euroneuro.2008.01.004_bib29","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/da.20019","article-title":"Generalized anxiety disorder and major depressive disorder comorbidity in the National Survey of Mental Health and Well-being","volume":"20","author":"Hunt","year":"2004","journal-title":"Depress. Anxiety"},{"key":"10.1016\/j.euroneuro.2008.01.004_bib30","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1017\/S0033291706009135","article-title":"The sources of co-morbidity between major depression and generalized anxiety disorder in a Swedish national twin sample","volume":"37","author":"Kendler","year":"2007","journal-title":"Psychol. Med."},{"key":"10.1016\/j.euroneuro.2008.01.004_bib31","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1001\/archpsyc.62.6.617","article-title":"Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication","volume":"62","author":"Kessler","year":"2005","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2008.01.004_bib32","doi-asserted-by":"crossref","first-page":"317","DOI":"10.7326\/0003-4819-146-5-200703060-00004","article-title":"Anxiety disorders in primary care: prevalence, impairment, comorbidity, and detection","volume":"146","author":"Kroenke","year":"2007","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.euroneuro.2008.01.004_bib33","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1212\/01.WNL.0000145767.36287.A1","article-title":"Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial","volume":"63","author":"Lesser","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.euroneuro.2008.01.004_bib34","series-title":"Evaluation of the Psychological Therapies","article-title":"Outpatient treatment of neurotic depression: medication and group psychotherapy","author":"Lipman","year":"1976"},{"key":"10.1016\/j.euroneuro.2008.01.004_bib35","unstructured":"Lyrica prescribing information. Available on the web at: https:\/\/www.lyrica.com\/cwpb\/v1\/begin.do?null."},{"key":"10.1016\/j.euroneuro.2008.01.004_bib36","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/sj.bjp.0704227","article-title":"Block by gabapentin of the facilitation of glutamate release from rat trigeminal nucleus following activation of protein kinase C or adenylyl cyclase","volume":"134","author":"Maneuf","year":"2001","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.euroneuro.2008.01.004_bib37","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1517\/14656566.7.15.2139","article-title":"Pregabalin for the treatment of generalised anxiety disorder","volume":"7","author":"Montgomery","year":"2006","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.euroneuro.2008.01.004_bib38","doi-asserted-by":"crossref","first-page":"771","DOI":"10.4088\/JCP.v67n0511","article-title":"Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine","volume":"67","author":"Montgomery","year":"2006","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2008.01.004_bib44","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1176\/appi.ps.57.12.1738","article-title":"Prevalence of generalized anxiety disorder in general practice in Denmark, Finland, Norway, and Sweden","volume":"57","author":"Munk-J\u01ffrgensen","year":"2006","journal-title":"Psychiatr. Serv."},{"key":"10.1016\/j.euroneuro.2008.01.004_bib39","series-title":"Poster Presentation at the 7th Annual International Forum on Mood and Anxiety Disorders, Budapest, Hungary, Dec 5\u20137","article-title":"Efficacy of pregabalin and venlafaxine-XR in generalized anxiety disorder","author":"Murphy","year":"2007"},{"issue":"4","key":"10.1016\/j.euroneuro.2008.01.004_bib60","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1017\/S1461145702003048","article-title":"Generalized anxiety disorder: comorbidity, comparative biology and treatment","volume":"5","author":"Nutt","year":"2002","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"Suppl 12","key":"10.1016\/j.euroneuro.2008.01.004_bib40","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1017\/S1092852900025803","article-title":"Understanding the neurobiology of comorbidity in anxiety disorders","volume":"10","author":"Nutt","year":"2006","journal-title":"CNS Spectr."},{"key":"10.1016\/j.euroneuro.2008.01.004_bib41","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1176\/appi.ajp.160.3.533","article-title":"Pregabalin in generalized anxiety disorder: a placebo-controlled trial","volume":"160","author":"Pande","year":"2003","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2008.01.004_bib42","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/01.jcp.0000155820.74832.b0","article-title":"Efficacy of pregabalin in the treatment of generalized anxiety disorder: double-blind, placebo-controlled comparison of BID versus TID dosing","volume":"25","author":"Pohl","year":"2005","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2008.01.004_bib43","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1097\/01.jcp.0000084025.22282.84","article-title":"Predictors of outcome following venlafaxine extended-release treatment of DSM-IV generalized anxiety disorder: a pooled analysis of short- and long-term studies","volume":"23","author":"Pollack","year":"2003","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2008.01.004_bib45","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0165-0327(97)00196-1","article-title":"Minor depressive disorder and subsyndromal depressive symptoms: functional impairment and response to treatment","volume":"48","author":"Rapaport","year":"1998","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.euroneuro.2008.01.004_bib46","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1176\/appi.ajp.159.4.637","article-title":"A descriptive analysis of minor depression","volume":"159","author":"Rapaport","year":"2002","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2008.01.004_bib47","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/00005053-196901000-00010","article-title":"Replication of factors of psychotherapy in interview, ward behaviour and self report ratings of hospitalized depressives","volume":"148","author":"Raskin","year":"1969","journal-title":"J. of Nerv. Ment. Dis."},{"key":"10.1016\/j.euroneuro.2008.01.004_bib48","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.jpain.2004.12.007","article-title":"Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial","volume":"6","author":"Richter","year":"2005","journal-title":"J. Pain"},{"key":"10.1016\/j.euroneuro.2008.01.004_bib49","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1001\/archpsyc.62.9.1022","article-title":"Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam","volume":"62","author":"Rickels","year":"2005","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2008.01.004_bib50","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.pain.2004.05.001","article-title":"Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial","volume":"110","author":"Rosenstock","year":"2004","journal-title":"Pain"},{"issue":"Suppl 13","key":"10.1016\/j.euroneuro.2008.01.004_bib51","first-page":"20","article-title":"Primary care perspectives on generalized anxiety disorder","volume":"65","author":"Roy-Byrne","year":"2004","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2008.01.004_bib52","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.pain.2004.01.001","article-title":"Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomised, placebo-controlled clinical trial","volume":"109","author":"Sabatowski","year":"2004","journal-title":"Pain"},{"issue":"Suppl 20","key":"10.1016\/j.euroneuro.2008.01.004_bib53","first-page":"22","article-title":"The Mini-international Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10","volume":"59","author":"Sheehan","year":"1998","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2008.01.004_bib59","article-title":"Pregabalin in central neuropathic pain associated with spinal cord injury: a placebo-controlled trial","volume":"28;67","author":"Siddall","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.euroneuro.2008.01.004_bib54","doi-asserted-by":"crossref","first-page":"523","DOI":"10.4088\/JCP.v62n07a04","article-title":"Efficacy of venlafaxine extended release in patients with major depressive disorder and comorbid generalized anxiety disorder","volume":"62","author":"Silverstone","year":"2001","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2008.01.004_bib55","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1080\/10401230590932335","article-title":"Escitalopram for the treatment of GAD: efficacy across different subgroups and outcomes","volume":"2","author":"Stein","year":"2005","journal-title":"Ann. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2008.01.004_bib56","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1185\/030079906X80404","article-title":"Efficacy and tolerability of pregabalin for treating pain and related sleep interference in postherpetic neuralgia: a 13-week, randomized trial","volume":"22","author":"Van Seventer","year":"2006","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.euroneuro.2008.01.004_bib57","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1002\/da.10065","article-title":"Generalized anxiety disorder: prevalence, burden, and cost to society","volume":"16","author":"Wittchen","year":"2004","journal-title":"Depress. Anxiety"}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X08000205?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X08000205?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,30]],"date-time":"2018-12-30T20:25:16Z","timestamp":1546201516000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X08000205"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,6]]},"references-count":60,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2008,6]]}},"alternative-id":["S0924977X08000205"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2008.01.004","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2008,6]]}}}